SEC Tracker
Get the app

Propanc Biopharma PPCB

Propanc Biopharma approves reverse stock split

Preliminary information statement (shareholder action already approved)

Form
PRE 14C
Filed
Importance
Routine
  1. Approved a reverse stock split ratio between 1:2 and 1:10
  2. Majority Stockholder (50.01% voting equity) approved the split
  3. Effective date pending Nasdaq approval
  4. Shares reduced from ~10.3M to ~1.0M - ~5.2M

Written from the PRE 14C on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Propanc Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cannapharmarx CPMD public float $3M, Jun 30, 2025
  2. MetaVia MTVA public float $3M, Jun 30, 2025
  3. Oragenics OGEN public float $3M, Jun 30, 2025
  4. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  5. PTC Therapeutics PTCT public float $3M, Jun 30, 2025